Extended Data Fig. 10: PILRα expression correlates with CD99, immune checkpoints, and patient survival across multiple cancer types.
From: PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity
a, Positive correlation between PILRA and CD99 mRNA expression in tumor tissues form patients with TNBC (n = 1100), GBM (n = 516), HNSC (n = 522), KIRP (n = 290), THCA (n = 509), and STAD (n = 415), as analyzed by TIMER. Spearman’s correlation coefficient and P-value are given (two-sided t-test). False discovery rate-adjusted p < 0.05. Regression line with standard error interval is shown. b, Kaplan–Meier analysis of overall survival stratified by median baseline of CD99 levels in TNBC (low = 82, high = 85), KIRC (low = 350, high = 180), KIRP (low = 209, high = 78), and STAD patients (low = 152, high = 219). Kaplan–Meier Plotter curves are typically analyzed using the log-rank (Mantel-Cox) test to compare survival distributions between groups. c,d, Positive correlation between the expression of PILRA mRNA and mRNA encoding immune checkpoints PD-1 (PDCD1), CTLA-4 (CTLA4), and TIM-3 (HAVCR2) in TNBC (n = 191) (c) and GBM (n = 153) (d) patients, as determined by TIMER analysis. Spearman’s correlation coefficient and P-value are given (two-sided t-test). False discovery rate-adjusted p < 0.05. Regression line with standard error interval is shown.
